TCMD TACTILE SYSTEMS TECHNOLOGY INC

CIK 0001027838 15 ready 8-Ks latest May 7, 2026, 7:59 PM ET RSS · JSON

Activity: ELEVATED 2 filings / 30d vs 0 baseline

Ready 8-Ks 15

Latest filing May 7, 2026, 7:59 PM ET

Top materiality 0.80

Event mix earnings ×8 · other_material ×4 · leadership ×2

Sentiment 5 pos · 2 neg · 8 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for TCMD

Highest-materiality recent filing

Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance

May 4, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
Net loss $1.8M ($0.08 per share) vs $3.0M loss in Q1 2025; gross margin 76.5% vs 74%.

Read filing →

May 7, 2026, 7:59 PM ET other material materiality 0.30 neutral item 5.03 item 5.07 item 9.01 ◈ Governance Changes

Tactile Systems shareholders approve director removal amendment, re-elect all directors

Stockholders approved amendment to allow director removal consistent with Delaware law; 14.9M For, 0.9M Against.
May 4, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance

Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
March 9, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01

Tactile Medical appoints Andrea Pearson to Board of Directors effective March 9, 2026

Pearson joins board and serves on Compliance & Reimbursement and Nominating & Corporate Governance committees.
February 17, 2026, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 7.01 item 9.01

Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M

Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.
November 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

Tactile Medical Q3 net income $8.2M, revenue up 17%; raises FY guidance and authorizes $25M buyback

Q3 revenue $85.8M (+17% YoY), net income $8.2M ($0.36 diluted EPS) vs $5.2M ($0.21) in Q3 2024.
August 4, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Tactile Systems Q2 revenue $78.9M (+7.8% YoY); net income $3.2M vs $4.3M; raises low-end of adj EBITDA guidance

Revenue $78.9M, up 7.8% YoY, ahead of prior expectations; gross margin improved to 75% from 74%.
May 9, 2025, 7:59 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01

Stockholders approve 2025 Equity Incentive Plan with 1.85M new shares; all board nominees elected

2025 Equity Incentive Plan approved, authorizing up to 1,850,000 new shares of common stock.
May 5, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance

Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.
February 18, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Tactile Medical Q4 rev $85.6M (+10%), net income $9.7M; guides FY25 rev $316-322M

Q4 total revenue $85.6M (+10% YoY); gross margin 75.2% vs 72.1% YoY.
January 13, 2025, 6:59 PM ET leadership materiality 0.55 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Tactile Medical appoints Laura King to Board of Directors effective Jan 13, 2025

Laura King elected to Board; serves on Audit and Compliance & Reimbursement Committees.
November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 8.01 item 9.01

Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback

Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.
August 5, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M

Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.
July 5, 2024, 7:59 PM ET litigation materiality 0.35 neutral item 7.01 item 8.01 item 9.01

Tactile Systems settles shareholder derivative lawsuit, agrees to governance reforms and $0.5M fee payment

Enters Stipulation of Settlement in derivative lawsuit Weaver v. Moen, dated June 6, 2024.
May 9, 2024, 7:59 PM ET other material materiality 0.20 neutral item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

Tactile Systems stockholders approve officer exculpation amendment at 2024 annual meeting

All eight director nominees elected; Valerie Asbury with 17.8M votes for, 442k withheld.
May 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

TCMD Q1 revenue up 4% to $61.1M, net loss $2.2M; reaffirms FY2024 outlook; CEO transition

Total revenue $61.1M (+4% YoY); lymphedema +5%, airway clearance -4%.

Executive changes

Appointed

Laura G. King

Director

TCMD · TACTILE SYSTEMS TECHNOLOGY INC

Effective: 2025-01-13
Filed: January 13, 2025, 6:59 PM ET

the board of directors of Tactile Systems Technology, Inc. (the “Company”) elected Laura G. King to serve as a member of the board and fixed the size of the board at nine directors, all effective as of January 13, 2025.

Earnings & guidance

2026-Q1 EPS reported -$0.08 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

5 positive 2 negative 8 neutral

source · TCMD on sec.gov